Nature Communications (Jun 2019)
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy
- Mónica Pascual-García,
- Ester Bonfill-Teixidor,
- Ester Planas-Rigol,
- Carlota Rubio-Perez,
- Raffaella Iurlaro,
- Alexandra Arias,
- Isabel Cuartas,
- Ada Sala-Hojman,
- Laura Escudero,
- Francisco Martínez-Ricarte,
- Isabel Huber-Ruano,
- Paolo Nuciforo,
- Leire Pedrosa,
- Carolina Marques,
- Irene Braña,
- Elena Garralda,
- María Vieito,
- Massimo Squatrito,
- Estela Pineda,
- Francesc Graus,
- Carmen Espejo,
- Juan Sahuquillo,
- Josep Tabernero,
- Joan Seoane
Affiliations
- Mónica Pascual-García
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Ester Bonfill-Teixidor
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Ester Planas-Rigol
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Carlota Rubio-Perez
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Raffaella Iurlaro
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Alexandra Arias
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Isabel Cuartas
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Ada Sala-Hojman
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Laura Escudero
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Francisco Martínez-Ricarte
- Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron University Hospital
- Isabel Huber-Ruano
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Paolo Nuciforo
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Leire Pedrosa
- Hospital Clinic, University of Barcelona and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)
- Carolina Marques
- Seve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Center, CNIO
- Irene Braña
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Elena Garralda
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- María Vieito
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Massimo Squatrito
- Seve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Center, CNIO
- Estela Pineda
- Hospital Clinic, University of Barcelona and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)
- Francesc Graus
- Hospital Clinic, University of Barcelona and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)
- Carmen Espejo
- Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron University Hospital
- Juan Sahuquillo
- Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron University Hospital
- Josep Tabernero
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- Joan Seoane
- Vall d Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
- DOI
- https://doi.org/10.1038/s41467-019-10369-9
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 11
Abstract
LIF is a pleiotropic cytokine that promotes an immunosuppressive microenvironment and has critical functions in embryonic development. Here, the authors show that LIF regulates CD8+ T cell tumor infiltration in cancer by repressing CXCL19 and promoting the presence of protumoral macrophages and thatLIF inhibition, via neutralizing antibodies, promotes T cell infiltration and synergizes with immune checkpoint inhbitors resulting in tumor regression and immunological memory.
